MannKind Corp. (MNKD)

[nobodysbusiness]

"...to solve the individual dosing issue"

Likely they can't. The trials showed that titration was difficult:



You can see that the lispro dose shows relatively little change from week 1-2 while afrezza required escalating doses steadily over two months -- up to 4 times the starting dose -- before finally starting to level off, and it looks like it might have started escalating again at 6 months but the study cut off at point.

Note also the much larger degree of variability -- compare the bars extending above and below the afrezza data points to those of lispro.

A recurring theme among regular prandial users is inconsistency in response to dosing.